Text Size

Opioid Rotation From Morphine to Methadone in Treatment of Non-Malignant Pain

This study has been completed.
Sponsor:
Information provided by:
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00356083
First received: July 24, 2006
Last updated: NA
Last verified: July 2006
History: No changes posted
  Purpose

Patients with non-malignant pain are switched from morphine to methadone with a nine-months' follow-up.


Condition Intervention Phase
Non-Malignant Chronic Pain
 Drug: Methadone
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Opioid Switching From Oral Slow Release Morphine to Oral Methadone May Improve Pain Control in Chronic Non-Malignant Pain: a Nine-Month Follow-Up Study.

Resource links provided by NLM:

MedlinePlus related topics: Chronic Pain
U.S. FDA Resources

Further study details as provided by Norwegian University of Science and Technology:

Estimated Enrollment: 12
Study Start Date: January 2004
Estimated Study Completion Date: January 2005
Detailed Description:

Twelve patients with poor pain control or unacceptable side effects during treatment with morphine were switched to methadone and followed for nine months in this open prospective study. Primary outcomes were patient preference for opioid and pain control while physical, cognitive and role functioning were secondary outcomes. The morphine dose was decreased by 1/3 daily and was replaced with an equianalgesic dose of methadone over a three-day period. During switching and a one-week dose titration period, patients were given additional methadone if required. During dose titration one patient experienced sedation requiring naloxone. Four patients were switched back to morphine due to poor pain control, drowsiness or sweating. Seven patients preferred long-term (>nine months) treatment with methadone and reported reduced pain and improved functioning while cognition was not improved. This study brings novel information on the long-term consequences for pain control, health-related quality of life and cognitive functioning with a switch from morphine to methadone in the treatment of chronic non-malignant pain.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-70 years of age
  • non-malignant chronic pain
  • morphine use

Exclusion Criteria:

  • addiction
  • kidney disorders
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00356083

Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Petter C. Borchgrevink, PhD MD Norwegian University of Science and Technology
Study Chair: Petter C Brochgrevink, MD PhD Norwegian University of Science and Technology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00356083     History of Changes
Other Study ID Numbers: 188-03REK
Study First Received: July 24, 2006
Last Updated: July 24, 2006
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Additional relevant MeSH terms:
Methadone
Morphine
Analgesics, Opioid
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
 Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents
Narcotics

ClinicalTrials.gov processed this record on May 22, 2013